Senti Biosciences Holdings, Inc.
No SEC Form 4 filings for $SNTI in the last 30 days.
See all $SNTI insider activity →Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On September 1, 2026, the Securities Purchase Agreement, dated April 27, 2026 (the “Purchase Agreement”), by and among the Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc (“Senti Holdings” or “Midco”), Se
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On August 14, 2026, Senti Holdings, Inc. (“Senti Holdings”), a wholly owned subsidiary of Senti Biosciences Holdings, Inc. (the “Company”), issued and sold to Celadon Partners SPV 24 (“Celadon”) $4.0 million in aggregate princ
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 exhibit21-agreementandplan.htm EX-2.1 Document Exhibit 2.1 ______________________________________________ AGREEMENT AND PLAN OF MERGER BY AND AMONG CELADON PARTNERS SPV 35 LIMITED, SENTI MERGER SUB, INC., SENTI BIOSCIENCES HOLDING, INC., SENTI HOLDINGS, INC., AND SENTI B
Over the past 7 days, alphai's AI scored 1 news story mentioning SNTI (Senti Biosciences Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent SNTI coverage spans financial news, corporate actions and earnings.
Potential delisting risk may pressure the stock lower; successful capital raise via notes could mitigate downside.
The note issuance creates a $4 M debt obligation and potential future equity conversion, modestly diluting existing shareholders.
The filing discloses a merger agreement structure and parties, which can drive deal-spread repricing and liquidity/arb positioning for SNTI.
Senti Biosciences' SENTI-202 therapy demonstrated promising efficacy in a Phase 1 trial for R/R AML, with significant response rates and excellent safety profile, potentially signaling upcoming positive developments for the company.
The increased institutional stake suggests confidence in SNTI's long-term prospects, potentially supporting share price stability or modest appreciation.
alphai scores every news story that mentions SNTI with an AI model for sentiment and relevance, and aggregates insider trades from Senti Biosciences Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Senti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On September 1, 2026, the Securities Purchase Agreement, dated April 27, 2026 (the “Purchase Agreement”), by and among the Senti Biosciences Holdings, Inc. (the “Company”), Senti Holdings, Inc (“Senti Holdings” or “Midco”), Se
2 min readSenti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry Into a Material Definitive Agreement. On August 14, 2026, Senti Holdings, Inc. (“Senti Holdings”), a wholly owned subsidiary of Senti Biosciences Holdings, Inc. (the “Company”), issued and sold to Celadon Partners SPV 24 (“Celadon”) $4.0 million in aggregate princ
2 min readSenti Biosciences Holdings, Inc. (SNTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-2.1 2 exhibit21-agreementandplan.htm EX-2.1 Document Exhibit 2.1 ______________________________________________ AGREEMENT AND PLAN OF MERGER BY AND AMONG CELADON PARTNERS SPV 35 LIMITED, SENTI MERGER SUB, INC., SENTI BIOSCIENCES HOLDING, INC., SENTI HOLDINGS, INC., AND SENTI B
6 min readSENTI-202, an off-the-shelf logic-gated CAR-NK cell therapy developed by Senti Biosciences (SNTI), demonstrated significant efficacy in a Phase 1 trial for high-risk relapsed/refractory Acute Myeloid Leukemia (R/R AML) patients. The therapy achieved a 50% overall response rate (ORR) and a 42% complete remission/complete remission with partial hematologic recovery (CR/CRh), with all CRs being MRD-negative, alongside strong safety. Senti Biosciences plans a pivotal trial for 2026 and intends to expand the platform into solid tumors.
3 min readNew Enterprise Associates 15, L.P. (NEA) has filed an amended Schedule 13D/A, disclosing a 12.1% stake in Senti Biosciences (SNTI), equating to 3,775,615 shares. The decrease in their percentage ownership (by more than 1%) is due to an increase in Senti's outstanding shares, not a result of NEA buying or selling shares. NEA holds these shares for investment purposes and currently has no specific plans for corporate actions.
2 min readSOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Senti Biosciences, Inc. ( Nasdaq: SNTI ) ( "Senti Bio" ) , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for ...
4 min readSOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- Senti Biosciences, Inc. ( NASDAQ:SNTI ) ( "Senti Bio" ) , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, MD, ...
3 min readIn-person presentation on Thursday, October 9th at 11:30 AM JST In-person presentation on Thursday, October 9th at 11:30 AM ...
2 min readSOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- Senti Biosciences, Inc. ( NASDAQ:SNTI ) ( "Senti Bio" ) , a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present ...
2 min readSOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 ( GLOBE NEWSWIRE ) -- Senti Biosciences, Inc.
3 min read
